Meta-Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Matthew F W Gee, Donald B Chalfin, Edward B De Vol et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the Enhanced Liver Fibrosis (ELF) test for identifying significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study analyzed 34 MASLD-focused studies and established Youden cutoffs: ≥F2 at 9.37, ≥F3 at 9.64, and F4 at 9.99, with corresponding AUROCs indicating good diagnostic performance.
Key findings
- Youden cutoff for ≥F2 fibrosis is 9.37 with an AUROC of 0.818.
- For ≥F3 fibrosis, the Youden cutoff is 9.64, also with an AUROC of 0.818.
- F4 fibrosis has a Youden cutoff of 9.99 and an AUROC of 0.774.
- ELF <9.00 may effectively rule out ≥F2 fibrosis in MASLD.
Why it matters
Accurate identification of liver fibrosis stages is crucial for managing patients with MASLD, as it informs treatment decisions and potential therapeutic interventions. The ELF test offers a non-invasive option for assessing fibrosis, which can enhance patient care.